Fig. 6

Systemic administration of Ago2 normalizes inflammatory activation and induces neuroprotection in the hippocampus. LPS-injected mice (LPS, 2 mg/kg) produced higher levels of Iba-1 (a) and S100B (b), and lower levels of CREB (c), MAP2 (d) and PSD-95 (e). Mice treated with Ago2 (0.4 nmol/L) had marker levels similar to sham controls (animals injected with phosphate-buffered saline, CTR), with the exception of the Iba-1 marker. Similar to the mouse cortex, the Ago2 hippocampus levels did not change significantly in the experimental conditions, with the exception of the Ago2-injected mice, in which a decrease of Ago2 levels occurred (f). NRP1 levels did not change significantly in any of the experimental conditions (g). The table summarizes data from these experiments (h). Data are expressed as the mean ± SEM of the indicated number of repeats and as a percentage relative to sham controls (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to sham controls; ^#p < 0.05, ^###p < 0.001, ^####p < 0.0001 compared to LPS-injected animals; one-way ANOVA; in c to e, Student’s t test was used for the comparison between CTR and LPS). Ago2 argonaute-2, CREB cAMP response element-binding protein, Iba-1 ionized calcium-binding adaptor molecule-1, LPS lipopolysaccharide, MAP2 microtubule-associated protein, NRP1 neuropilin-1, PSD-95 postsynaptic density protein-95, S100B S100 calcium-binding protein B